Additional studies on the mediators of the insulin-dependent signalling pathways at the protein level and their functional consequences as well as the presence of metabolic disorders would therefore be invaluable for the identification of novel therapeutic targets that may be modified at an earlier stage in the patients with UM or melanocytic lesions. The gene discussed is INS; the disease is Other metabolic disease.